Tazid - IM/IV 500Injection

Indications of Tazid IM/IV 500mg Injection

Tazid IM/IV 500mg Injection is suitable for the treatment of patients with infections caused by designated biologically sensitive strains in the following diseases:

Lower respiratory tract infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas, Haemophilus influenza, including ampicillin resistance Strains cause; Klebsiella; Enterobacter; Proteus mirabilis; Escherichia coli; Serratia; Citrobacter; Osteococcal pneumonia; and Staphylococcus aureus (a strain sensitive to methicillin).

Skin and skin structure infections caused by Pseudomonas aeruginosa; Klebsiella; Escherichia coli; Proteus, including Proteus mirabilis and India-positive Proteus, Enterobacter; Serratia; Staphylococcus aureus (Methicillin-sensitive strain); and Streptococcus pyogenes (group A β-hemolytic streptococcus).

Complex and uncomplicated urinary tract infections caused by Pseudomonas aeruginosa; Enterobacter; Proteus, including Proteus mirabilis and India-positive Proteus, Klebsiella; and Escherichia coli.

Bacterial sepsis is caused by Pseudomonas aeruginosa, Klebsiella, Haemophilus influenza, Escherichia coli, Serratia, Streptococcus pneumonia and Staphylococcus aureus (methicillin-sensitive strains).

Bone and joint infections and Staphylococcus aureus (methicillin-sensitive strains) caused by Pseudomonas aeruginosa, Klebsiella, and Enterobacter.

Gynecological infections, including endometritis, pelvic cellulitis, and other infections of the female reproductive system caused by E. coli.

Intra-abdominal infections, including peritonitis caused by Escherichia coli, Klebsiella, and Staphylococcus aureus (methicillin-sensitive strains), and a variety of microbial infections caused by aerobic and anaerobic organisms and Bacteroides.

Central nervous system infections, including meningitis caused by Haemophilus influenza and Neisseria meningitidis, Pseudomonas aeruginosa, and Streptococcus pneumonia.

Pharmacology of Tazid IM/IV 500mg Injection

Ceftazidime is a semi-adult, broad-spectrum and beta-lactam antibiotic for parenteral administration. Safftgeidemic is the bactericide of the action that has its effect on the inhibition of the enzymes involved in the synthesis of cellular liquids. A wide range of guide organizations is susceptible to ceftazidiments in vitro, including strains that are resistant to gentamicin and other aminoglycosides. In addition, it is shown that SaffTageIDIM is active for positive pepper-picked organisms. It is very stable for most betales, plasmids, or clinically important chromosomes produced by particulate organisms and accumulator organisms, as a result of ampicillin and other cephalosporins is active for many strains that are resistant. 

Tazid IM/IV 500mg Injection Dosage & Administration

The usual adult dosage is 1 gram administered intravenously or intramuscularly every 8 to 12 hours. The dosage and route should be determined by the susceptibility of the causative organisms, the severity of the infection and the condition, and the renal function of the patient.

Ceftazidime is to be used by the parenteral route, the dosage depending upon the severity, sensitivity & type of infections, and the age, weight & renal function of the patient.

Adults: The adult dosage range for ceftazidime is 1 to 6 gm per day 8 or 12 hourly (IM/IV) in the majority of infections, 1 gm 8 hourly or 2 gm 12 hourly should be given.

• In urinary tract infections and many less serious infections: 500 mg or 1 gm 12 hourly is usually adequate.
• In severe infections, especially immunocompromised patients, including those with neutropenia: 2 gm 8 or 12 hourly should be administered. When used as a prophylactic agent in prostatic surgery 1 gm should be given at the induction of anesthesia. A second dose should be considered at the time of catheter removal.

Elderly: In view of the reduced clearance of Ceftazidime in acutely ill elderly patients, the daily dosage should not normally exceed 3 gm, especially in those over 80 years of age.

• Cystic fibrosis: In fibrocystic adults with a normal renal function who have pseudomonal lung infections, high doses of 100 to 150 mg/kg/day as three divided doses should be used.

Infants and Children: The usual dosage range for children aged over two months is 30 to 100 mg/kg/day, given as two or three divided doses. Doses up to 150 mg/kg/day (maximum 6 gm daily) in three divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis.

Neonates and Children up to 2 months of age: The usual dosage range is 25 to 60 mg/kg/day as two divided doses.

Ceftazidime may be given intravenously or by deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral proof of the thigh. Intra-arterial administration should be avoided. For IV/IM administration, Ceftazidime should be reconstituted with the supplied Sterile Water for Injection.

Contraindications of Tazid IM/IV 500mg Injection

Ceftazidime is contraindicated in patients who have shown hypersensitivity to Ceftazidime or the cephalosporin group of antibiotics.

Tazid IM/IV 500mg Injection Side Effects

Local responses following IV injection, as well as allergy and gastrointestinal problems, are the most prevalent adverse effects. Pruritus, rash, and fever are hypersensitivity responses. Rarely, angioedema and anaphylaxis have been recorded. Diarrhea, nausea, vomiting, and stomach discomfort are among gastrointestinal symptoms. Headache, dizziness, and paresthesia were all symptoms of the central nervous system.

Pregnancy & Lactation

Ceftazidime has not been subjected to sufficient and well-controlled trials in pregnant women. Because animal reproduction studies do not always anticipate human response, this medication should only be taken during pregnancy if absolutely necessary.

Ceftazidime is excreted in modest quantities in human milk during lactation. Because many medicines are excreted in human milk and the safety of the injectable component in nursing infants has not been proved, a choice should be made between discontinuing breastfeeding and discontinuing the drug, taking into consideration the drug's value to the mother.

Precautions & Warnings

When Ceftazidime is given to individuals with renal impairment, the total daily dose should be decreased. Ceftazidime should be used with caution in those who have had gastrointestinal problems, especially colitis.

Therapeutic Class

Third Generation Cephalosporins

Storage Conditions

Store below 25°C, protected from light and moisture. Reconstituted solutions are stable for up to 24 h if stored between 2°-8°C.

Pharmaceutical Name of Tazid IM/IV 500mg Injection

Square Pharmaceuticals Limited

Generic

Ceftazidime Pentahydrate